Affiliation:
1. Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
2. Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba 4428164, Israel
Abstract
An ultra-performance liquid chromatography with photodiode array (UPLC-PDA) UV detection method was developed here for the first time for simple, rapid, selective and sensitive quantification of the commonly prescribed selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib in low plasma volumes (50 μL). The method includes protein precipitation followed by liquid–liquid extraction, evaporation and reconstitution. A gradient mobile phase of 75:25 going to 55:45 (v/v) water:acetonitrile (1 mL/min flow rate) was applied. Total run time was 8 min, representing a significant improvement relative to previous reports. Excellent linearity (r2 = 1) was obtained over a wide (0.1–12 µg/mL) etoricoxib concentration range. Short retention times for etoricoxib (4.9 min) and the internal standard trazodone (6.4 min), as well as high stability, recovery, accuracy, precision and reproducibility, and low etoricoxib LOD (20 ng/mL) and LOQ (100 ng/mL), were achieved. Finally, the method was successfully applied to a pharmacokinetic study (single 20 mg/kg orally administered etoricoxib mini-capsule) in rats. In conclusion, the advantages demonstrated in this work make this analytical method both time- and cost-efficient for drug monitoring in pre-clinical/clinical settings.
Funder
Israeli Ministry of Innovation, Science and Technology
Reference30 articles.
1. Single dose oral etoricoxib for acute postoperative pain in adults;Clarke;Cochrane Database Syst. Rev.,2014
2. Etoricoxib;Cochrane;Drugs,2002
3. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib;Takemoto;Clin. Pharmacokinet.,2008
4. Gonzalez-Alvarez, I., Bermejo, M., Tsume, Y., Ruiz-Picazo, A., Gonzalez-Alvarez, M., Hens, B., Garcia-Arieta, A., Amidon, G.E., and Amidon, G.L. (2021). An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 13.
5. High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection;Matthews;J. Chromatogr. B Biomed. Sci. Appl.,2001